SCHEMBL6435499

SCHEMBL6435499

COc1ccc(O)c(C(=NN)c2nc3nonc3nc2Nc2cccc(Cl)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
GFER P55789 1/20 0.41
AKR1C3 P42330 1/20 0.41
AKR1C2 P52895 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.39
KDR P35968 1/20 0.39
EGFR P00533 5/20 0.39
ERBB3 P21860 1/20 0.39
CDK1 P06493 3/20 0.38
ABL1 P00519 2/20 0.38
PRKCA P17252 2/20 0.38
SRC P12931 1/20 0.38
MAPT P10636 2/20 0.38
TP53 P04637 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6436126 0.94 FADS1 (0.43) FADS1SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL6439207 0.91 MEN1 (0.38) FADS1SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL6439214 0.91 MEN1 (0.38) FADS1SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL6418364 0.91 TP53 (0.43) FADS1SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL6418345 0.91 TP53 (0.43) FADS1SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL6417043 0.88 SMN1; SMN2 (0.38) FADS1SMN1; SMN2MEN1KMT2AKDR
SCHEMBL6417864 0.88 APP (0.42) SMN1; SMN2MEN1KMT2AKDREGFR
SCHEMBL6415753 0.87 TP53 (0.41) FADS1SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL6415756 0.87 TP53 (0.41) FADS1SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL6417908 0.85 TNF (0.40) FADS1SMN1; SMN2MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 FADS1 1439/4885SMN1; SMN2 4369/4885MEN1 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.